Tratamiento De La Diabetes Mellitus

TRATAMIENTO DE LA DIABETES MELLITUS

OBJETIVOS DEL TRATAMIENTO DE LA DM ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ÉXITO DEL TRATAMIENTO DE LA DM ,[object Object],[object Object],[object Object],[object Object],[object Object]

METAS EN EL TRATAMIENTO DE LA DM2 Sociedade Brasileira de Diabetes 1999 < 150 TRIGLICÉRIDOS (mg/dl) 20-25 ÍNDICE DE MASA CORPORAL (kg/m 2 ) < 135 < 80 ,[object Object],[object Object],PRESIÓN ARTERIAL (mmHg) < 200 > 45 < 100 ,[object Object],[object Object],[object Object],COLESTEROL (mg/dl) Hasta el límite superior del método GLUCO-HEMOGLOBINA 126 160 110 140 ,[object Object],[object Object],ACEPTABLE IDEAL GLUCOSA PLASMÁTICA (mg/Dl)

LECCIONES DEL UKPDS UK Prospective Diabetes Study Group. Lancet 1998 UK Prospective Diabetes Study Group. BMJ 1998 ,[object Object],[object Object]

HIPOGLUCEMIANTES ORALES ,[object Object],[object Object],[object Object],[object Object],[object Object]

Objetivos del control de la glucemia ,[object Object],[object Object],[object Object]

SULFONILUREAS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SULFONILUREAS ,[object Object],[object Object],[object Object]

SULFONILUREAS DE I A GENERACIÓN ,[object Object],[object Object],[object Object],[object Object]

SULFONILUREAS DE I A GENERACIÓN ,[object Object],[object Object],[object Object]

SULFONILUREAS DE II A GENERACIÓN ,[object Object],[object Object],[object Object],[object Object]

SULFONILUREAS DE II A GENERACIÓN ,[object Object],[object Object],[object Object],[object Object],[object Object]

SULFONILUREAS DE II A GENERACIÓN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

BIGUANIDAS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

BIGUANIDAS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

METFORMIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

METFORMIN ,[object Object],[object Object],[object Object],[object Object],[object Object]

METFORMIN ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

TIAZOLIDINEDIONAS PIO y ROSIGLITAZONA ,[object Object],[object Object],[object Object],[object Object]

TIAZOLIDINEDIONAS ,[object Object],[object Object],[object Object],[object Object]

TIAZOLIDINEDIONAS ,[object Object],[object Object]

INHIBIDORES DE LA  GLUCOSIDASA ,[object Object],[object Object],[object Object],[object Object]

ACARBOSA y MIGLITOL ,[object Object],[object Object],[object Object],[object Object]

MEGLITINIDAS ,[object Object],[object Object],[object Object],[object Object],[object Object]

REPAGLINIDA Y NATEGLINIDA ,[object Object],[object Object],[object Object],[object Object]

DM2 Y RESP UE STA TERAP É UTICA ,[object Object],[object Object]

INDICA CION ES PARA USO DE INSULINA E N LA DM2 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PERFIL PROMEDIO DE ACCIÓN DE LAS INSULINAS HUMANAS Y ANIMALES * Adaptado de: Medical management of type 1 diabetes – 3 rd edition - 1998 - American Diabetes Association Análogos de insulina 24 24 No tiene 4 Glargina 24-36 24-36 Mínimo 8-14 Ultralenta (U) 20-24 16-20 8-14 4-6 Lenta (L) 20-24 16-20 8-14 4-6 NPH (N) 6-10 4-6 3-4 0,5-2,0 Rápida (R) Duración Máxima Duración Efectiva Pico Inicio PERFIL DE ACCIÓN (horas) INSULINAS ANIMALES 20-24 18-20 10-16 6-10 Ultralenta (U) 16-20 12-18 6-12 2-4 Lenta (L) 13-14 10-16 6-10 2-4 NPH (N) 6-8 3-6 2-3 0,5 - 1,0 Rápida (R) 4-6 3-4 0,5-1,5 < 0,25 Ultra-Rápida (UR) Duración Máxima Duración Efectiva Pico Inicio PERFIL DE ACCIÓN (horas) INSULINAS HUMANAS

EL IDEAL D E L A ACCIÓN INSULÍNICA BASAL ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

ANÁLOGOS DE INSULINA ,[object Object],[object Object],[object Object],[object Object]

Lepore, et al. Diabetes . 1999;48(suppl 1):A97. 6 5 4 3 2 1 0 0 10 Tiempo (h) despues de inyeción SC Fin del período de observación 20 30 Glargina NPH Tasa de utilización de glucosa (mg/kg/h) Perfiles de acción con Clamp de glucosa INSULINA GLARGINA PERFIL TERAPEUTICO

ANÁLOGOS DE INSULINA ,[object Object],[object Object],[object Object],[object Object],[object Object]

Incretinas ,[object Object],[object Object],[object Object],[object Object],[object Object]

Incretinas ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

INSULINA INHALADA ,[object Object],[object Object],[object Object],[object Object],[object Object]

Tratamiento De La Diabetes Mellitus

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (20)

Similar to Tratamiento De La Diabetes Mellitus

Similar to Tratamiento De La Diabetes Mellitus (20)

More from Dr. Carlos López Carrillo

More from Dr. Carlos López Carrillo (20)

Recently uploaded

Recently uploaded (20)

Tratamiento De La Diabetes Mellitus